
levodopa pharmacokinetic variability in Parkinson's disease, and we agree that gastrointestinal determinants of treatment response extend beyond gastric emptying. However, our review was deliberately focused on gastroparesis, while explicitly acknowledging that levodopa is absorbed in the duodenum and proximal jejunum and that gastrointestinal dysfunction in Parkinson's disease may involve more generalized transit abnormalities, small intestinal bacterial overgrowth, and gut microbiota-related mechanisms. Importantly, prolonged small bowel transit alone does not establish the direction or magnitude of its effect on levodopa bioavailability, nor does current evidence demonstrate that intestinal dysmotility is a more direct or predominant determinant than delayed gastric emptying. Rather than opposing gastric and intestinal mechanisms, we propose that gastric emptying, small bowel motility, and other pharmacokinetic, pharmacodynamic, and disease-related factors should be viewed as sequential, interdependent, and patient-specific determinants of levodopa response. Integrated studies combining gastrointestinal transit assessment, levodopa pharmacokinetics, and motor outcomes are therefore warranted.
LRRK2 is implicated in the Parkinson's disease (PD) microbiome–gut–brain axis. We compared plasma lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14), markers of gut permeability and endotoxin exposure, in PD patients with/without LRRK2 p.G2385R and/or p.R1628P and controls, and examined their associations with systemic inflammation and clinical severity. Neither marker differed between groups. Among PD patients, LBP correlated with higher IL-6, TNF-α, and worse motor function, while sCD14 correlated with higher IL-6, CCL5, and worse constipation, with no LRRK2 risk variant-specific associations. Further prospective longitudinal studies are warranted to determine the clinical significance of these associations.
Background Reduced presynaptic density, commonly referred to as synaptic loss, is an early and clinically relevant feature of parkinsonian disorders. The development of positron emission tomography (PET) radiotracers targeting synaptic vesicle glycoprotein 2A (SV2A) has enabled in vivo quantification of synaptic density. Objectives This systematic review examines neuroimaging methodologies and regional SV2A PET findings in Parkinson's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Methods A systematic search of PubMed, Scopus, and Web of Science was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines, including studies employing validated SV2A PET radiotracers to quantify synaptic density in parkinsonian populations. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Substantial methodological heterogeneity precluded meta-analysis; findings were synthesized narratively. Results Fourteen studies were included. In PD, the substantia nigra was the most affected region, with striatal involvement more prominent in advanced disease (>6 years duration). In PSP and CBD, synaptic loss was widespread, exceeded grey matter atrophy, and correlated with clinical severity and cognitive decline; longitudinal PSP data showed reductions of approximately 3–4% per year in frontal and caudate regions. In MSA, infratentorial involvement (cerebellum, pons, medulla) predominated, enabling diagnostic differentiation with high accuracy (AUC up to 0.99). Conclusions SV2A PET reveals disease-specific patterns of reduced presynaptic availability, consistent with synaptic loss, across parkinsonian disorders, supporting its potential as a diagnostic and monitoring biomarker. Methodological harmonization and longitudinal multicenter studies are needed to establish clinical utility.
Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S129-α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S129-α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.
The accumulation of aggregated alpha-synuclein (aSyn) in the brain is one of the defining pathological features in Parkinson's Disease, Parkinson's Disease with Dementia, Lewy Body Dementia, and Multiple System Atrophy. For this reason, this group of disorders is collectively known as synucleinopathies. The identification of autosomal dominant mutations in the gene encoding aSyn (SNCA) in hereditary forms of disease further supports a central role for this protein in pathogenesis. The Synuclein Workshop was held for the first time in 2025 and is intended to be organized regularly every 2 years in countries of Latin America. The purpose of this series of workshops is to bring together leading experts in the field of synucleinopathies in a part of the world that is known for a strong tradition in the field, and to enable early career researchers to engage with and learn from other renowned experts, with the overall goal of discussing and advancing research in the field. In 2025, the Synuclein Workshop took place in Villa La Angostura, a city located in the province of Neuquén, Argentina. The meeting, entitled "The Patagonia Synuclein Workshop 2025", brought together 100 scientists studying both clinical and biomolecular aspects of synucleinopathies. The meeting covered many of the open questions in the field, in a format that promoted and encouraged open and unbiased discussions between the participants, and underscored the need for additional research that, hopefully, will lead to the development of new diagnostic tools and therapeutic strategies. Here, we provide a summary of the main topics discussed in the meeting, and highlight what is the current knowledge in the field, what we still do not know, and the future directions necessary for achieving the ultimate goal of the community: to offer better options to patients, families, and care-givers.